We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Comen Medical

LifeSign LLC

LifeSign is a medical diagnostic company delivering rapid point of care testing solutions for caregivers in critical ... read more Featured Products: More products

Download Mobile App

Carolina Liquid Chemistries Offers FDA Emergency Use Authorized POC COVID-19/Flu A&B Combo Test

By HospiMedica International staff writers
Posted on 24 Mar 2021
Print article
Image: Status COVID-19/Flu A&B Combo Test (Photo courtesy of LifeSign LLC)
Image: Status COVID-19/Flu A&B Combo Test (Photo courtesy of LifeSign LLC)
Carolina Liquid Chemistries, Corp. (CLC, Greensboro, NC, USA) has made yet another addition to its Point-of-Care product line by offering the Emergency Use Authorized Status COVID-19/Flu A&B Combo Test from LifeSign LLC (Skillman, NJ, USA).

The Status COVID-19/Flu A&B Combo Test is a lateral flow immunoassay intended for the in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, Influenza A, and Influenza B directly from nasopharyngeal swab specimens obtained from individuals, who are suspected of respiratory viral infection consistent with COVID-19 and/or influenza by their healthcare provider, within the first five days of onset of symptoms.

To respond effectively to the COVID-19 outbreak, rapid detection of cases, stringent performance assessment, and increase in the current diagnostic capacity are still urgently needed. As the early symptoms of COVID-19 are similar to those of seasonal Influenza A or B, a rapid detection test to specifically diagnose symptomatic patients is urgently needed. The Status COVID-19/Flu A&B Combo Test is intended to aid in the rapid differential diagnosis of Influenza A, B, and SARS-CoV-2 viral infection.

"The Status COVID-19/Flu A&B Combo Test is a vital combination test for the current market. Anytime we can make testing easier, faster, less expensive, and more efficient for the patient and provider, we know we are doing our job," said Phil Shugart, CEO of Carolina Liquid Chemistries Corp.

Related Links:
Carolina Liquid Chemistries, Corp.
LifeSign LLC

Print article



view channel
Image: Respicardia’s remedē System (Photo courtesy of Respicardia, Inc.)

Zoll Medical Acquires CSA Systems Manufacturer Respicardia

ZOLL Medical Corporation (Chelmsford, MA, USA), an Asahi Kasei company, has acquired Respicardia, Inc. (Minnetonka, MN, USA), a provider of novel implantable neurostimulators for the treatment of moderate... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.